Seattle Genetics (SGEN)

Add to Watchlists
Create an Alert
55.79 +0.42  +0.76% NASDAQ May 25, 20:00 Delayed 2m USD

Seattle Genetics Research and Development Expense (Quarterly):

152.50M for March 31, 2018
View 4,000+ financial data types
View Full Chart

Seattle Genetics Research and Development Expense (Quarterly) Chart

Export Data
Save Image
Print Image

Seattle Genetics Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 2001. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2018 152.50M
Dec. 31, 2017 110.50M
Sept. 30, 2017 113.61M
June 30, 2017 114.41M
March 31, 2017 118.18M
Dec. 31, 2016 108.17M
Sept. 30, 2016 92.71M
June 30, 2016 85.55M
March 31, 2016 92.87M
Dec. 31, 2015 74.61M
Sept. 30, 2015 70.79M
June 30, 2015 85.74M
March 31, 2015 63.40M
Dec. 31, 2014 64.04M
Sept. 30, 2014 58.51M
June 30, 2014 53.69M
March 31, 2014 54.50M
Dec. 31, 2013 50.77M
Sept. 30, 2013 67.85M
June 30, 2013 52.27M
March 31, 2013 47.74M
Dec. 31, 2012 47.66M
Sept. 30, 2012 41.39M
June 30, 2012 42.76M
March 31, 2012 38.49M
Dec. 31, 2011 40.24M
Sept. 30, 2011 41.08M
June 30, 2011 49.64M
March 31, 2011 32.43M
Dec. 31, 2010 32.52M
Sept. 30, 2010 44.29M
June 30, 2010 39.29M
March 31, 2010 30.32M
Dec. 31, 2009 28.92M
Sept. 30, 2009 28.26M
June 30, 2009 28.71M
March 31, 2009 33.25M
Dec. 31, 2008 37.58M
Sept. 30, 2008 27.71M
June 30, 2008 23.50M
March 31, 2008 22.15M
Dec. 31, 2007 20.11M
Sept. 30, 2007 17.74M
June 30, 2007 15.18M
March 31, 2007 11.80M
Dec. 31, 2006 11.08M
Sept. 30, 2006 9.797M
June 30, 2006 10.01M
March 31, 2006 9.251M
Dec. 31, 2005 8.537M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More


SGEN Research and Development Expense (Quarterly) Benchmarks

PerkinElmer 45.98M
Sangamo Therapeutics 23.55M
Acorda Therapeutics 30.56M

SGEN Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 50.77M Dec 2013
Maximum 152.50M Mar 2018
Average 84.23M

SGEN Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("SGEN", "r_and_d_expense")
  • Last 5 data points: =YCS("SGEN", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.




Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.